The FDA has approved a potential game-changing test for the novel coronavirus (COVID-19).
Late Friday, Abbott Laboratories (NYSE: ABT) announced the U.S. Food and Drug Administration issued Emergency Use Authorization for the fastest available molecular point-of-care test for the detection of novel coronavirus, which can deliver positive results in as little as five minutes and negative results in 13 minutes.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, Abbott's president and chief operating officer. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."
This is GAME CHANGER. Abbott to market, starting next week, a fast point-of-care #coronavirus test, delivering positive results in 5min and negative results in 13min. Will deliver 50K tests/day to start. Kudos to Abbott and FDA's Jeff Shuren and team at CDRH who are in the fight.
— Scott Gottlieb, MD (@ScottGottliebMD) March 28, 2020
Abbott will make ID NOW COVID-19 tests available next week to health care providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today.
Abbott's stock closed Friday's session at $74.56 per share.
How The Coronavirus Is Impacting Everyday Lives
Markets End Historically Volatile Week On Uneven Note
See more from Benzinga
- A New Arsenal? Trump Greenlights US Automakers To Produce Ventilators, Other Metal Products
- Bezos Says Amazon Is Focused On Helping The Fight Against Coronavirus
- Danaher's Cepheid Receives FDA Emergency Use Authorization For 45-Minute Coronavirus Test
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.